Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Explore this paper's citation graph
Summary
Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with n ivolumAB alone than with ipil optimumab alone.
- Type
- article
- Published
- 2017-09-11
- Cited by
- 3,418
- References
- 15
- Access
- Open access
- OpenAlex
- https://openalex.org/W2753432434
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205102506
Keywords
Ipilimumab, Nivolumab, Medicine, Melanoma, Oncology
References
- Measuring diagnostic and predictive accuracy in disease management: an introduction to receiver operating characteristic (ROC) analysis.
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- A sharper Bonferroni procedure for multiple tests of significance
- Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
- Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
- Pembrolizumab versus Ipilimumab in Advanced Melanoma.
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
- Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma
- Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038
- Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.
- The American Association for Cancer Research Annual Meeting.
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
Cited by
- Immunological effects of BRAF+MEK inhibition
- Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
- T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers
- Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
- Biomarker Discovery in Immunotherapy-treated Melanoma Patients with Imaging Mass Cytometry
- Genomic Applications in Pathology
- Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD1‐Antikörper beim metastasierten Melanom
- Clinical Trials Corner
- The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
- The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors
- Control of NK Cell Activation by Immune Checkpoint Molecules
- Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies
- Immune Checkpoint Inhibitors in Melanoma and HIV Infection
- Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
- Introduction to the Special Issue on Cancer Immunotherapy
- Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
- Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy.
- Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives
- Axillary Metastatic Melanoma of Unknown Primary: A Case Report and Systematic Review
- Moving treatments earlier to move further forward
Related papers
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.
- First-line treatment of metastatic melanoma: role of nivolumab
- Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
- Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma
- Serum protein predictors of long term survival from combined ipilimumab and nivolumab therapy in metastatic melanoma patients.
- Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM)
- Figure S3 from Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas